These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 14663138)

  • 1. Epstein-Barr virus activates beta-catenin in type III latently infected B lymphocyte lines: association with deubiquitinating enzymes.
    Shackelford J; Maier C; Pagano JS
    Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15572-6. PubMed ID: 14663138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription.
    Bonvini P; An WG; Rosolen A; Nguyen P; Trepel J; Garcia de Herreros A; Dunach M; Neckers LM
    Cancer Res; 2001 Feb; 61(4):1671-7. PubMed ID: 11245482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The deubiquitinating enzyme Fam interacts with and stabilizes beta-catenin.
    Taya S; Yamamoto T; Kanai-Azuma M; Wood SA; Kaibuchi K
    Genes Cells; 1999 Dec; 4(12):757-67. PubMed ID: 10620020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accumulation of cytoplasmic beta-catenin and nuclear glycogen synthase kinase 3beta in Epstein-Barr virus-infected cells.
    Everly DN; Kusano S; Raab-Traub N
    J Virol; 2004 Nov; 78(21):11648-55. PubMed ID: 15479806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. beta-catenin is a target for the ubiquitin-proteasome pathway.
    Aberle H; Bauer A; Stappert J; Kispert A; Kemler R
    EMBO J; 1997 Jul; 16(13):3797-804. PubMed ID: 9233789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.
    Levitskaya J; Sharipo A; Leonchiks A; Ciechanover A; Masucci MG
    Proc Natl Acad Sci U S A; 1997 Nov; 94(23):12616-21. PubMed ID: 9356498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus oncogenesis and the ubiquitin-proteasome system.
    Masucci MG
    Oncogene; 2004 Mar; 23(11):2107-15. PubMed ID: 15021898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of beta-catenin levels and localization by overexpression of plakoglobin and inhibition of the ubiquitin-proteasome system.
    Salomon D; Sacco PA; Roy SG; Simcha I; Johnson KR; Wheelock MJ; Ben-Ze'ev A
    J Cell Biol; 1997 Dec; 139(5):1325-35. PubMed ID: 9382877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells.
    Rice PL; Kelloff J; Sullivan H; Driggers LJ; Beard KS; Kuwada S; Piazza G; Ahnen DJ
    Mol Cancer Ther; 2003 Sep; 2(9):885-92. PubMed ID: 14555707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor viruses and cell signaling pathways: deubiquitination versus ubiquitination.
    Shackelford J; Pagano JS
    Mol Cell Biol; 2004 Jun; 24(12):5089-93. PubMed ID: 15169876
    [No Abstract]   [Full Text] [Related]  

  • 11. Differential interaction of plakoglobin and beta-catenin with the ubiquitin-proteasome system.
    Sadot E; Simcha I; Iwai K; Ciechanover A; Geiger B; Ben-Ze'ev A
    Oncogene; 2000 Apr; 19(16):1992-2001. PubMed ID: 10803460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma cell lines contain a proteasome-sensitive, nuclear cytoskeleton-associated pool of beta-catenin.
    Bonvini P; Hwang SG; el-Gamil M; Robbins P; Neckers L; Trepel J
    Ann N Y Acad Sci; 1999; 886():208-11. PubMed ID: 10667221
    [No Abstract]   [Full Text] [Related]  

  • 13. The ubiquitin/proteasome system in Epstein-Barr virus latency and associated malignancies.
    Dantuma NP; Masucci MG
    Semin Cancer Biol; 2003 Feb; 13(1):69-76. PubMed ID: 12507558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus-encoded latent membrane protein 1 activates beta-catenin signaling in B lymphocytes.
    Tomita M; Dewan MZ; Yamamoto N; Kikuchi A; Mori N
    Cancer Sci; 2009 May; 100(5):807-12. PubMed ID: 19309363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes.
    Wen W; Iwakiri D; Yamamoto K; Maruo S; Kanda T; Takada K
    J Virol; 2007 Jan; 81(2):1037-42. PubMed ID: 17079287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of the ITAM and PY motifs of Epstein-Barr virus latent membrane protein 2A in the inhibition of epithelial cell differentiation and activation of {beta}-catenin signaling.
    Morrison JA; Raab-Traub N
    J Virol; 2005 Feb; 79(4):2375-82. PubMed ID: 15681438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway.
    Lai KY; Chou YC; Lin JH; Liu Y; Lin KM; Doong SL; Chen MR; Yeh TH; Lin SJ; Tsai CH
    J Virol; 2015 Jun; 89(11):5968-80. PubMed ID: 25810549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous detection of the two main proliferation driving EBV encoded proteins, EBNA-2 and LMP-1 in single B cells.
    Rasul AE; Nagy N; Sohlberg E; Ádori M; Claesson HE; Klein G; Klein E
    J Immunol Methods; 2012 Nov; 385(1-2):60-70. PubMed ID: 22921685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple signal transducers and activators of transcription are induced by EBV LMP-1.
    Zhang L; Hong K; Zhang J; Pagano JS
    Virology; 2004 May; 323(1):141-52. PubMed ID: 15165826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: Possible correlation with specific caspase-dependent cleavage of beta-catenin and inhibition of beta-catenin-mediated transactivation.
    Cervello M; Giannitrapani L; La Rosa M; Notarbartolo M; Labbozzetta M; Poma P; Montalto G; D'Alessandro N
    Int J Mol Med; 2004 May; 13(5):741-8. PubMed ID: 15067380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.